Nuvation Bio Inc. is trading 5.5% down at $4.66 as the stock undergoes consolidation following a significant rally driven by analyst optimism.
- The stock recently surged 13.3% on June 9, 2026, after RBC Capital hiked its price target to $20 with an Outperform rating.
- Today’s pullback is characterized as normal consolidation and profit-taking amid a broadly weaker market following last week's sharp gains.